ABSTRACT
concentrations
(MICs) are consistently \0.125 lg/ml, much lower than most other anti-MRSA agents. Dalbavancin possesses an extended half-life of over 1 week, allowing an initial dose of 1000 mg followed by 500 mg 1 week later to complete a course of therapy for ABSSSI. It is approximately 95% protein bound and is widely distributed throughout the body, achieving concentrations similar to plasma levels in numerous tissues. Against MRSA, dalbavancin Standards Institute (CLSI) [3] . However, isolates with reduced susceptibility are increasing in the literature after first being reported 20 years ago [4, 5] . Even when vancomycin therapy is appropriate, the management of the antibiotic is complicated.
Nephrotoxicity is often associated with vancomycin therapy, and its narrow therapeutic index makes it the only currently available antibiotic with a consensus guideline statement regarding its dosing [6] . This additional side chain allows dalbavancin to anchor to the bacterial cell membrane, enhancing its potency, prolonging its half-life, and allowing for extended dosing intervals [12] . Dalbavancin also possesses an amidated carboxyl side group that enhances the agent's anti-staphylococcal activity. The structure of dalbavancin is detailed in Fig. 1 .
Like other agents in its class, dalbavancin exerts its antimicrobial activity through interaction with terminal D-alanyl-D-alanine residues of peptidoglycan precursors [13] . The binding of dalbavancin to these terminal residues prevents both transpeptidase and transglycosylase enzymes from catalyzing peptidoglycan cross-linking and thereby destroying the integrity of the cell wall, ultimately causing cell death [12] . Recent data have demonstrated that the lipophilic side chain of dalbavancin allows dimerization of the molecule and anchors dalbavancin to lipid II in the cellular membrane, strengthening adherence to the D-alanyl-D-alanine target site and allowing for enhanced activity compared to vancomycin and teicoplanin [14] .
Microbiology and Resistance
Dalbavancin possesses in vitro activity against several gram-positive pathogens, including S. aureus, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus anginosus, Enterococcus faecium, and Enterococcus faecalis, although activity against enterococci has not been observed clinically [9, [15] [16] [17] [18] . Against staphylococci and streptococci, dalbavancin possesses 8-16-fold greater in vitro activity than vancomycin in broth microdilution MIC testing [15, 16] . Currently, the FDA has an MIC breakpoint established for only S. aureus, S. pyogenes, S. agalactiae, and S. anginosus of B0.125 lg/ml [8] . Population data of more than 1100 staphylococci and 300 b-hemolytic Although this activity is worth noting, the vast majority of vancomycin-resistant enterococci in the United States possess VanA [24] . A complete breakdown of currently available dalbavancin MIC data against gram-positive organisms is available in Table 1 .
Dosing, Pharmacokinetics, and Pharmacodynamics
Dalbavancin is currently FDA-approved at a dose of 1000 mg on day 1 followed by 500 mg dosing regimen was based on a clinical study evaluating complicated skin and skin structure infections (cSSSI) in which dalbavancin dosed at 1000 mg initially followed by 500 mg on day 8
was numerically superior to a one-time dose of 1100 mg [33] . Nearly 33% of dalbavancin is excreted in the urine unchanged, suggesting that non-renal methods of elimination play an important role in the metabolism of dalbavancin [28] . The extended half-life of dalbavancin is largely due to extensive, reversible binding to serum albumin, estimated to be roughly 95% [34] . Among both healthy subjects and those with varying degrees of renal dysfunction, the maximum concentration (C max ) of dalbavancin falls between 248 and 312 lg/ml following the standard 1000 mg initial dose [28, 30] .
Dalbavancin exhibits a large volume of distribution, with an initial average of 8-12 L and an ultimate volume of distribution of up to 15 L once the drug has distributed throughout the tissues [32] . Data from nine healthy male subjects given 1000 mg demonstrate that dalbavancin maintains concentrations in skin blister fluid well above current MIC 90 values through 7 days, suggesting that dalbavancin will be active for the duration of ABSSSI treatment [35] . In a pharmacokinetic study of dalbavancin in patients with varying renal and hepatic function, area under the curve (AUC) values were markedly elevated over the treatment duration for patients with creatinine clearances (CrCl) of 30 ml/min relative to patients with normal renal function [30] . Because of its reduced clearance, patients with renal impairment (CrCl\30 ml/min) should have dalbavancin doses adjusted to 750 mg initially followed by 375 mg on day 8 for a complete treatment course. Interestingly, dalbavancin is not efficiently cleared by hemodialysis and levels are similar between patients on dialysis and those with normal renal function [30] . Therefore, although it seems contradictory to data in patients with CrCl \30 ml/min, patients on regularly scheduled hemodialysis do not require dosage adjustment. The same study found that hepatic function had no appreciable affect on dalbavancin clearance and likely does not need to be taken into account when dosing, although caution should be exercised in moderate to severe hepatic impairment, as clinical data are limited.
The pharmacokinetic parameter associated with efficacy of dalbavancin both in vitro and in vivo is the ratio of AUC to MIC, as is generally the case with glycopeptides [36] . In the initial pharmacokinetic studies, bactericidal concentrations of dalbavancin were present in Dalbavancin has also been studied in several animal models of infection. When dalbavancin was evaluated against S. aureus and S. pneumoniae in neutropenic murine thigh and lung models, it was determined that AUC:MIC and C max :MIC were both correlated with dalbavancin activity [36] . These data formed the dosing regimens used in human studies.
In a study published by Lefort et al., dalbavancin possessed activity against vancomycin-susceptible S. aureus (VSSA) and VISA dependent upon dose in a rabbit model of endocarditis [40] . In the authors' in vitro time kill studies, dalbavancin possessed superior activity to teicoplanin and vancomycin against VSSA and VISA. However, dalbavancin was not bactericidal in the endocarditis model. The authors postulated that, due to the enhanced clearance of dalbavancin in rabbits compared to people, drug exposures were not appropriate for bactericidal activity, although they may be in humans.
Further studies evaluating additional dosing options in the setting of endocarditis are needed. Dalbavancin has also been studied in a foreign-body infection model in guinea pigs both alone and in combination with rifampin [41] . Dalbavancin alone was unable to eradicate adherent MRSA, but it was able to prevent resistance to rifampin. The combination of agents was effective and superior to either agent alone, suggesting that rifampin may play an important role in therapy targeting biofilm infections.
Clinical Trials
In addition to the study that led to its approval for ABSSSI, dalbavancin has been previously evaluated clinically in the setting of complicated skin and skin structure infections Dalbavancin concentrations remained [30 lg/ ml for 1 week after the 1100 mg dalbavancin dose, and concentrations remained [20 lg/ml for 20 days in patients who received 1000 mg followed by 500 mg. Adverse effects were mild and considered to be unrelated to study drug. The data from this study established that dalbavancin is likely optimally dosed at 1000 mg with a supplementary 500 mg dose 1 week later for skin infections. Jauregui et al. were the first to evaluate dalbavancin at 1000 mg followed by 500 mg 1 week later in a phase III trial for the treatment of cSSSI [44] . The study was a multicenter, non-inferiority trial comparing dalbavancin to linezolid for 14 days. Enrollment criteria were similar to the study by Seltzer and colleagues.
The primary end point was clinical success, defined as the lack of necessary further antibacterial therapy. The treatment groups were similar at baseline except for a higher proportion of vascular disease in the dalbavancin group. The average age was 47 years, and 62% of patients were male.
Abscess (32%) and cellulitis (28%) were the primary types of infection. Efficacy at test-of-cure for dalbavancin was 88.9% and was 91.2% for linezolid (lower limit CI -7.28%), which achieved non-inferiority. The vast majority of cultured isolates were from abscesses, with 90% of those isolates being S.
aureus, and dalbavancin and linezolid cured 91% and 89% of these isolates, respectively. Adverse events were generally mild, and adverse events related to treatment were higher in the linezolid arm compared to dalbavancin (32.2-25.4%, respectively).
Boucher and colleagues evaluated dalbavancin dosed at 1000 mg followed by 500 mg in two phase III, randomized controlled trials comparing dalbavancin to standard therapy against ABSSSI, DISCOVER 1 and owing to high cure rates in these patients with incision and drainage alone, and at least 25% of patients had fever, establishing a less healthy population than previous studies. Per recent FDA guidance, the primary endpoint was cessation of spread of erythema and a temperature of B37.6°C at 48-72 h. More than 85% of patients enrolled possessed temperatures C38°C, and the median size of infection was 343 cm 2 . The majority of patients were white (89.3%) with a mean age of 49.5 years. Greater than 50% of patients met SIRS criteria, and \26% of patients had abscesses. results have yet to be published, but preliminary data presented in a press release suggest that the one-time dose of 1500 mg is similar to the two-dose regimen with regard to C20% reduction in ABSSSI lesion size at 48-72 h.
Although conclusions cannot be made without the full breadth of data available, it does appear that dalbavancin may be efficacious and safe with a one-time dose, further enhancing its therapeutic ease of use.
Safety and Drug Interactions
The safety of dalbavancin has been evaluated in several clinical and pre-clinical studies.
Combined phase II and phase III data thus far have revealed the most common adverse effects to be nausea (5.5%), headache (4.7%), diarrhea (4.4%), vomiting (2.8%), rash (2.7%), and pruritus (2.1%) [10, 28-30, 33, 42] . In the phase II study of CR-BSI, dalbavancin patients experienced more hypokalemia (6/33, 18%) and hypotension (7/33, 21%) than those treated with vancomycin, although these trends did not continue across other studies [42] .
Additionally, dalbavancin has demonstrated a 0.8% rate of ALT levels greater than three times the upper limit of normal, although these have been reversible with treatment cessation [8] . In the phase III clinical trials, treatment-related adverse events were fewer in the dalbavancin arms compared to treatment with vancomycin or linezolid [10, 44] . In contrast to the nephrotoxic effects often associated with glycopeptides, dalbavancin has not been associated with nephrotoxicity to date. Dalbavancin has already demonstrated efficacy in CR-BSI, and further studies will be important to determine its place in deep-seated infections such as pneumonia, osteomyelitis, and endocarditis. Preliminary data are promising, as dalbavancin achieves concentrations in bone tissue well above staphylococcal MIC 90 values 14 days after a 1000 mg dose [47] . Going forward, it will be imperative to determine optimal dosing strategies for infections that require weeks-long durations of therapy. Owing to the activity dalbavancin possesses in vitro and in vivo against S. aureus with reduced vancomycin susceptibility, further study involving dalbavancin against these isolates is also intriguing and warranted. It remains to be seen whether antibiotic combinations with dalbavancin will display similar additive effects as they do with vancomycin and daptomycin against gram-positive pathogens. Dalbavancin has the potential to be an effective agent to combat resistant gram-positive organisms, and expanded use of this agent post-approval will help determine its ultimate place in therapy. 
